Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors

Yi Qian (), Jorge Arellano, A. Brett Hauber, Ateesha F. Mohamed, Juan Marcos Gonzalez, Guy Hechmati, Francesca Gatta, Stacey Harrelson and Cynthia Campbell-Baird
Additional contact information
Yi Qian: Amgen Inc.
Jorge Arellano: Amgen Inc.
A. Brett Hauber: RTI Health Solutions
Ateesha F. Mohamed: RTI Health Solutions
Juan Marcos Gonzalez: RTI Health Solutions
Guy Hechmati: Amgen (Europe) GmbH
Francesca Gatta: Amgen (Europe) GmbH
Stacey Harrelson: Carolina Urologic Research Center
Cynthia Campbell-Baird: Pennsylvania State University Milton S. Hershey Medical Center

The Patient: Patient-Centered Outcomes Research, 2016, vol. 9, issue 4, No 5, 323-333

Abstract: Abstract Background Bone-targeted agents (BTAs) used for the prevention of skeletal-related events (SREs) associated with metastatic bone disease possess different attributes that factor into treatment decisions. Objective The aim of this study was to evaluate preferences of patients, caregivers, and nurses for features of BTAs used to prevent SREs in patients with a self-reported physician diagnosis of bone metastasis from solid tumors. Methods Patients (n = 187), primary caregivers (n = 197), or nurses (n = 196) completed a web-enabled discrete-choice experiment (10-question survey) in which they chose between pairs of hypothetical profiles of BTAs. Each profile was defined by six key treatment attributes, including efficacy and safety (two each) and route/frequency of administration and cost (one each). The relative importance of treatment attributes and levels was estimated. Results The most important treatment attribute for patients and nurses was out-of-pocket cost, and for caregivers, treatment-related risk of renal impairment. Risk of renal impairment was the second most important attribute for patients and nurses, while time until first SRE was the third most important attribute for all respondents. For nurses, risk of osteonecrosis of the jaw was least important, and for patients and caregivers, mode of administration was least important. Limitations Respondents considered hypothetical medications; therefore, their decisions may not have the same consequences as actual decisions. Conclusions The perspectives of patients, caregivers, and nurses are integral when making treatment decisions about BTAs to prevent SREs associated with solid tumors. Identifying the relative importance of attributes of BTAs will aid in the proper selection of therapy in this setting, which may improve patient outcomes.

Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40271-015-0158-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:9:y:2016:i:4:d:10.1007_s40271-015-0158-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-015-0158-4

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().